Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [2] - The company utilizes its GeneTAC platform to create therapies that target specific disease-causing genes [2] - Upcoming investor conferences will feature management participation in fireside chats, with live webcasts available [1][3] Company Overview - Design Therapeutics is developing a new class of therapies based on GeneTAC gene targeted chimera small molecules [2] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, and DT-818 for myotonic dystrophy type-1 [2] - The company is also advancing a program for Huntington's disease and exploring multiple genomic medicine discovery efforts [2]

Core Insights - Design Therapeutics, Inc. has appointed Justin Gover to its Board of Directors, effective immediately, bringing over 25 years of biotechnology leadership experience [1][2] - Gover's previous role as founding CEO of GW Pharmaceuticals included guiding the company through a $7 billion acquisition by Jazz Pharmaceuticals and the successful commercialization of Epidiolex® [2] - Dr. Arsani William has stepped down from the Board, having provided strategic counsel since 2021, including support for the company's IPO and clinical pipeline advancement [3] Company Overview - Design Therapeutics is a clinical-stage biotechnology company focused on developing GeneTAC gene-targeted therapies aimed at addressing serious degenerative genetic diseases [5] - The company's GeneTAC molecules are designed to modulate the expression of disease-causing genes, with ongoing clinical programs for Friedreich ataxia (DT-216P2), Fuchs endothelial corneal dystrophy (DT-168), myotonic dystrophy type-1, and Huntington's disease [5] - Discovery efforts are also underway for multiple genomic medicines, indicating a broad pipeline potential [5] Leadership Insights - Justin Gover's expertise in translating innovative science into medicines is expected to be invaluable for advancing Design's clinical pipeline [4] - Dr. William expressed pride in the progress made during his tenure, particularly in advancing the GeneTAC platform and establishing a transformative pipeline for genetic diseases [4] - Gover's involvement with other biotech boards and nonprofit organizations highlights his commitment to the industry and patient advocacy [4]

Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] Company Overview - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to create a new class of therapies aimed at modifying the expression of disease-causing genes [3] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, with additional programs in myotonic dystrophy type-1 and Huntington's disease [3] - Design Therapeutics is also engaged in discovery efforts for multiple genomic medicines [3] Upcoming Events - Management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on September 4, 2025, at 10:55 a.m. ET in New York [1] - A live webcast of the event will be available on the company's website and archived for at least 30 days [2]

Company Overview - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company utilizes a platform of GeneTAC gene targeted chimera small molecules to modulate the expression of disease-causing genes [3] Upcoming Presentation - Management will present at the 2025 Jefferies Global Healthcare Conference on June 4, 2025, at 2:35 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website and archived for at least 30 days [2] Product Development - The company is advancing clinical-stage programs including DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy [3] - Additional programs are in development for myotonic dystrophy type-1 and Huntington's disease, with ongoing discovery efforts for multiple genomic medicines [3]

Core Insights - Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious degenerative genetic diseases [3] - The company will participate in a fireside chat at the 2025 RBC Capital Markets Healthcare Conference on May 20, 2025 [1] - A live webcast of the event will be available and archived for at least 30 days [2] Company Overview - Design Therapeutics is developing a new class of therapies using its GeneTAC platform, which targets specific disease-causing genes [3] - Current clinical-stage programs include DT-216P2 for Friedreich ataxia and DT-168 for Fuchs endothelial corneal dystrophy, along with programs for myotonic dystrophy type-1 and Huntington's disease [3] - The company is also engaged in discovery efforts for multiple genomic medicines [3]